Lilly’s GLP-1 momentum faces new test with upcoming launches and valuation concerns

Eli Lilly’s rapid growth driven by GLP-1 drugs faces scrutiny as the company prepares for new product launches amid high valuations, with investors keenly awaiting Q2 results for further signals of sustained momentum. Eli Lilly may have delivered only modest…













